Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Bellicum Pharmaceuticals
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02065869CT.gov Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | — | Terminated | — | — | — |
NCT03301168CT.gov Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteopetrosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bpx-501 T Cells (this asset) | Bellicum Pharmaceuticals | P1/2 | CC · 47 |
| Fludarabine | Masonic Cancer Center, University of Minnesota | P2/3 | BB |
| Alemtuzumab | Masonic Cancer Center, University of Minnesota | P2/3 | BB |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P2/3 | BB |
| Interferon Gamma-1B | FDA Office of Orphan Products Development | P3 | B |
| Cyclophosphamide | Columbia University | P2/3 | B |
| Rabbit Anti-Thymocyte Globulin | Columbia University | P2/3 | B |
| Horse Anti-Thymocyte Globulin | Columbia University | P2/3 | CCC |
| Cald Hr-D | Masonic Cancer Center, University of Minnesota | P2 | CCC |
+1 more in the Osteopetrosis cohort
Other indications for Bpx-501 T Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Childhood Acute Myeloid Leukemia | — | P1/2 | CC · 47 |
| Inborn Error Of Immunity | — | P1/2 | CC · 47 |
| Aplastic Anemia | — | P1/2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bpx-501 T Cells in Osteopetrosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bpx-501-t-cells-osteopetrosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →